Skip to main content
Jun 3, 2016 12:48 PM UTC
Question

Pharmaceutical Cold Supply Chain Thought Leadership and ThingWorx

Although this presentation is from 5 years ago, its value is relevant today.  ThingWorx can play a key role in helping address this business challenge to make it a ThingWorx Partner opportunity -

Future (today?) - 50% of newly approved pharmaceuticals will be (are?) Biopharmaceuticals

  • Biopharmaceuticals have a fragile nature and are potentially sensitive to their environment from manufacturing to consumer usage
  • ONE OF THE MAJOR FACTORS IN MAINTAINING THE QUALITY AND INTEGRITY OF BIOPHARMACEUTICALS / BIOSIMILARS IS CONTROL OF STORAGE AND TRANSPORTATION TEMPERATURES.
    • Biopharmaceutical manufacturers have direct responsibility for, and control over, the correct storage and handling of their products from the start of production until products reach the first point of shipment
    • Beyond the first point of shipment, these manufacturers have only an indirect influence BUT they can be severely impacted by any failing from this point on
      • critical for them to educate and "understand" how their biopharmaceuticals are moving through the entire Cold Supply Chain